



CORRIGENDUM

A Multi-Center Study of the Prevalence and Characteristics of Eosinophilic Phenotype and High IgE Levels Among Chinese Patients with Severe Asthma [Corrigendum]

Ko FWS, Wang JKL, Hui DSC, et al. *J Asthma Allergy*. 2023;16:173-182.

The authors have advised there is an error in Table 1.

Table 1 on Page 177, in the third-to-last row, data addressing Median (IQR) for Eosinophil count, cells/mm³ should read from 3.2 (1.7, 6.0) to 240.0 (110.0, 410.0).

The authors apologize for this error.

Correct Table 1:

Characteristic	N=232
Skin prick test, positive, n (%) ^b	34 (73.9)
Comorbidities, n (%)	
Rhinitis	156 (93.4)
Nasal polyps	17 (10.2)
Sinusitis	2 (1.2)
Atopic dermatitis	30 (18.0)
Asthma associated with NSAIDs	0 (0)
Aspergillosis	0 (0)
Eczema	13 (7.8)
Treatment, n (%)	
ICS/LABA	232 (100)
LAMA	75 (39)
LTRA	154 (81)
Chronic OCS	8 (3.4)
Level of asthma symptom control, n (%)	
Well-controlled	67 (29)
Partly controlled	92 (40)
Uncontrolled	73 (31)
Number of severe exacerbations in the last year, n (%)	
0	175 (75)
1	28 (12)

(Continued)



Characteristic	N=232
2	10 (4)
3	9 (4)
>3	10 (4)
Lung function test ^c	
Pre-bronchodilator FEV ₁ , L	2.0±0.8
Post-bronchodilator FEV ₁ , L	2.0±0.6
Pre-bronchodilator % of the predicted FEV ₁ value, %	79.7±22.8
Post-bronchodilator % of the predicted FEV ₁ value, %	83.8±18.4
Pre-bronchodilator FEV ₁ / FVC, %	68.2±15.0
Post-bronchodilator FEV ₁ / FVC, %	71.0±13.2
Eosinophil count, cells/mm ³	
Mean±SD	312.7±281.6
Median (IQR)	240.0 (110.0, 410.0)
% Eosinophil count, %	
Mean±SD	4.3±3.7
Median (IQR)	3.2 (1.7, 6.0)
Total serum IgE, IU/mL	
Mean±SD	390.5±912.2
Median (IQR)	123.0 (40.8, 371.5)

Notes: ^an=231; ^bn=46; ^cn=57.

Abbreviations: ICS, inhaled corticosteroid; IQR, interquartile range; LABA, long-acting β_2 agonists; LAMA, long-acting muscarinic antagonists; LTRA, leukotriene receptor antagonists; OCS, oral corticosteroid; SD, standard deviation.

Publish your work in this journal

The Journal of Asthma and Allergy is an international, peer-reviewed open-access journal publishing original research, reports, editorials and commentaries on the following topics: Asthma; Pulmonary physiology; Asthma related clinical health; Clinical immunology and the immunological basis of disease; Pharmacological interventions and new therapies. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/journal-of-asthma-and-allergy-journal>